anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: To establish the prevalence and agreement between reported and observed leg weakness in people with sciatica. To establish which factors mediate any identified difference between reported and observed leg weakness in people with sciatica.
METHODS: 68 people with a clinical diagnosis of sciatica, records from spinal service, secondary care NHS Hospital, England, UK reviewed. Primary outcome measures were the sciatica bothersome index for reported leg weakness and the Medical Research Council scale for observed weakness. Agreement was established with Cohen's Kappa and intraclass correlation coefficient. Potential factors that may mediate a difference between reported and observed weakness included leg pain, sciatica bothersome index sensory subscale, age, hospital anxiety and depression subscale for anxiety.
RESULTS: 85% of patients reported weakness but only 34% had observed weakness. Cohen's Kappa (0.066, 95% CI - 0.53, 0.186; p = 0.317)] and ICC 0.213 (95% CI - 0.26, 0.428, p = 0.040) both showed poor agreement between reported and observed weakness. The difference between reported and observed measures of weakness was mediated by the severity of leg pain (b = 0.281, p = 0.024) and age (b = 0.253, p = 0.042).
CONCLUSION: There is a high prevalence of reported leg weakness in people with sciatica, which is not reflected in observed clinical measures of weakness. Differences between reported and observed weakness may be driven by the severity of leg pain and age. Further work needs to establish whether other objective measures can detect patient reported weakness.
PURPOSE:To obtain a new amidinocyclohexane derivative, having inhibitory action on proteolytic enzymes and useful as a medicine. CONSTITUTION:The amidinocyclohexane derivative of formula I [R is phenyl which may have a substituent group; (n) is 0-2] and its stereoisomer of formula II, e.g. 4-t-butylphenyl 3-(trans-4'-amidinocyclohexyl)propionate. The compounds of formulas I and II are obtained by esterifying new compounds of formulas III and IV with a compound of the formula ROH. The compounds are capable of effectively acting on suppression of cell proliferation or pancreatitis. Inhibiting actions on trypsin, thrombin, etc., are cited as the inhibiting action on enzymes.
<P>PROBLEM TO BE SOLVED: To provide an improved dental composition for whitening teeth, and to provide a method for using the same.  <P>SOLUTION: This composition producing chlorine dioxide in an amount effective to clearly change the whiteness of the surfaces of teeth is used. The composition comprises the first component having a chlorine dioxide precursor and the second component having a sour agent capable of contacting with the precursor to produce the chlorine dioxide. When the first component and the second component are mixed with each other to produce the chlorine dioxide, the composition has pH within the range of about 3.0 to about 4.5. In order to whiten the teeth, the first component and the second component are mixed with each other, and the consequently obtained mixture can be applied to the teeth. Or, one of the first component and the second component can first be applied to the teeth, and thereafter the other is applied. The composition is formulated to cause a clear change in the whiteness of the surfaces of the teeth in a relatively short time.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
Group A - PRF plus AFG with a CAF: The PRF will be prepared according to the protocol outlined by Choukroun 1. Prior to the surgical procedure, venous blood will be collected via venipuncture from the antecubital vein using one 10 ml sterile glass tube and one 10ml sterile plastic tube. The tubes will be immediately centrifuged at 1300 rpm for 8 minutes to obtain PRF. The fibrin clot formed in the middle part of the tube will be collected. The clot will be transferred to the PRF box and compressed to form a membrane. For the AFG, the liquid will be separated from the red blood cells from the plastic tube using a sterile syringe.
Using a single-group, prospective design, potential participants will be identified and screened for eligibility by the PI (LWJ) via medical record review of patients scheduled for their primary adjuvant chemotherapy consultation at DUMC and Durham VA. As a routine part of clinical care, during the treatment consultation the attending oncologist will perform a physical examination to screen for cardiovascular risk factors, the results of which will be recorded in the patients' medical records. Immediately following their consultation and oncologist approval, potential participants will be provided with a thorough review of the study by the principal investigator (LJ) and asked if they are willing to participate. Interested participants will be given an information package that provides further information on study participation. Two to five days following their treatment consultation and prior to the initiation of chemotherapy, interested participants will be contacted by telephone by the PI to answer any questions and to schedule the baseline assessment visit. At the baseline visit, participants will be asked to sign the informed consent and will be given a copy for their records. After consent, they will be given a baseline ECG and physician monitored cardiopulmonary exercise test (stress test) to screen for undiagnosed cardiovascular disease. Following the successful completion of baseline assessments, all participants will be scheduled for their initial exercise training session. Finally, on a different group of patients we will perform a random retrospective medical chart review of 50 completely-resected NSCLC patients who received usual care (i.e., no exercise training) during the study period to obtain comparative information on the treatment toxicity/compliance rate. The chart review will be performed by Drs. Jones, Garst and Crawford and will assess treatment toxicity and compliance over the entire course of adjuvant chemotherapy.
Study participation by invitation after complete pre-surgical work up at UC Davis Health System. Patients will be invited to participate if they meet all inclusion criteria's after completing all necessary clinical visits including lab studies, counseling, and participation in educational programs. During the pre-operative visit patients interested in participation will complete all necessary consent documentation. Pre-operative labs (blood and urine) will be collected along with additional blood, urine, and fecal samples will be collected pre-operatively. During surgery (Roux-en-Y Gastric Bypass surgeries only) tissue collection will include subcutaneous \& omental fat, jejunum, and liver biopsy. Post surgery patient will be observed for weight loss and resolution of co-morbidities. At designated times post surgery when lab studies are ordered additional blood/urine samples will be collected and analyzed.
BACKGROUND: Neuroinflammation substantially contributes to the pathology of Alzheimer's disease (AD), the most common form of dementia. Studies have reported that nuclear factor erythroid 2-related factor 2 (Nrf2) attenuates neuroinflammation in the mouse models of neurodegenerative diseases, however, the detailed mechanism remains unclear.
METHODS: The effects of dimethyl fumarate (DMF), a clinically used drug to activate the Nrf2 pathway, on neuroinflammation were analyzed in primary astrocytes and AppNL-G-F (App-KI) mice. The cognitive function and behavior of DMF-administrated App-KI mice were evaluated. For the gene expression analysis, microglia and astrocytes were directly isolated from the mouse cerebral cortex by magnetic-activated cell sorting, followed by quantitative PCR.
RESULTS: DMF treatment activated some Nrf2 target genes and inhibited the expression of proinflammatory markers in primary astrocytes. Moreover, chronic oral administration of DMF attenuated neuroinflammation, particularly in astrocytes, and reversed cognitive dysfunction presumably by activating the Nrf2-dependent pathway in App-KI mice. Furthermore, DMF administration inhibited the expression of STAT3/C3 and C3 receptor in astrocytes and microglia isolated from App-KI mice, respectively, suggesting that the astrocyte-microglia crosstalk is involved in neuroinflammation in mice with AD.
CONCLUSION: The activation of astrocytic Nrf2 signaling confers neuroprotection in mice with AD by controlling neuroinflammation, particularly by regulating astrocytic C3-STAT3 signaling. Furthermore, our study has implications for the repositioning of DMF as a drug for AD treatment.
A method for the treatment of erectile dysfunction comprises instilling intra meatally an aqueous solution containing prostaglandin-containing liposomes, a lysing agent for lysing the liposomes, and a papaverine solution. A pharmaceutical composition for treating erectile dysfunction comprises a three-component system. The first component comprises a predetermined amount of prostaglandin-containing liposomes, preferably lyopholized. The second component comprises a predetermined volume of an aqueous solution containing a lysing agent, preferably PEG(9) octylphenyl ether, for lysing the liposomes. The third component comprises a papaverine solution. Dissolution of the prostaglandin-containing liposomes and addition of the papaverine solution to the mixture yields a liquid composition suitable for application to the penis, preferably intra meatally, to effect erection.
Y chromosome short tandem repeats (Y-STRs) typing is a useful tool in scenarios such as mass graves analysis or disaster victim identification and has become a routine analysis in many laboratories. Not many comparisons have been performed with the currently available commercial kits, much less with degraded skeletal remains. This research aims to evaluate the performance of three commercial Y-STR kits: Yfiler™ Plus, PowerPlex® Y23, and Investigator® Argus Y-28 in 63 degraded skeletal remains from mass graves. PowerPlex® Y23 yields more reportable markers and twice the RFU on average, while Yfiler™ Plus and Investigator® Argus Y-28 exhibited a similar behaviour. Additionally, Argus Y-28, which has not been tested with this kind of samples in literature before, showed a good performance. Finally, a predictive model was attempted to be developed from quantification and autosomal STR data. However, no acceptable model could be obtained. Nevertheless, good Y-STR typing results may be expected if at least 50 pg DNA input is used or 13 autosomal markers were previously obtained.
This is an open-label, randomized controlled trial aimed to evaluate the efficacy and safety of using convalescent plasma for treating hospitalized patients with COVID-19. Participants must be adult hospitalized patients with a confirmed diagnosis of COVID-19 and time Between symptom onset and inclusion ≤ 7 days. Two hundred participants will be randomized in a 1:1 ratio to receive either 200-400 mL of high-titer COVID-19 convalescent plasma or standard care. The primary endpoint is the proportion of patients with clinical improvement at day 14 following randomization, defined by an increase of two points in the 7-point ordinal scale based on that recommended by the World Health Organization. Safety will be daily assessed by monitoring the occurrence of adverse effects and reactions to convalescent plasma transfusion. Study visits will occur on Day 1, Day 3, Day 7, and Day 14 or until hospital discharge, whichever comes first.
PURPOSE:To improve the absorbing property of sebum by specifying the bulk density of the paper formed from a paper material combined with a specific quantity of an inorganic loading material into a pulp raw material mainly made of vegetable fibers. CONSTITUTION:A pulp raw material made of vegetable fibers alone of a constituent A or a pulp raw material containing at least one kind selected among wood pulp, polyolefin synthetic pulp, and synthetic fibers in vegetable fibers is dispersed in water. The pulp raw material dispersed in water is applied with beating process to obtain the flexible and dense paper. An inorganic loading material of a constituent B is combined into the pulp raw material applied with beating process within the range of 5-50 pts.wt. to 100 pts.wt. of the pulp raw material of the constituent A to form the paper material for the dressing absorbent paper. When this paper material is made into paper and dried by the ordinary paper making method, the dressing absorbent paper can be manufactured. The dressing absorbent paper normally having the weighing of 10-30g/m<2>, the bulk density of 0.7 or above, and excellent absorbing property of sebum can be obtained.
The objective is to provide a composition or a food material for protecting a living body from an external factor, which includes an extract from  Agaricus Blazei Murill . The composition protects a living body through immunocompetent cells. The immunocompetent cells may be macrophages, and optionally, T cells. The immunocompetent cells may be antibody producing cells. The composition may protect a living body through an enhancement of humoral immunity. The enhancement of the humoral immunity may be caused by activating lymphocytes selected from the group consisting of activating T cells and macrophages, and thus enhancing expression of interleukin selected from the group consisting of interleukin-1β and interleukin 6. The external factor may be taken by smoking, or may be an antigen substance.
Patients continue their standard of care anti-PD-1 therapy. Treatment may consist of the following regimens: 1) nivolumab IV over 30 minutes Q2W or Q4W; 2) pembrolizumab IV over 30 minutes Q3W or Q6W; 3) nivolumab IV over 30 minutes and ipilimumab IV Q3W for 4 doses followed by nivolumab IV over 30 minutes Q2W or Q4W; or 4) pembrolizumab IV over 30 minutes and ipilimumab IV Q3W for 4 doses followed by pembrolizumab IV over 30 minutes Q3W or Q6W. Treatment continues until 52 weeks from start of standard of care anti-PD-1 therapy in the absence of disease progression or unacceptable toxicity.
A method of introducing biological material into cells includes providing one or more target cells and establishing a spray of substantially dispersed particles including biological material. The substantially dispersed particles have an electrical charge applied thereto such that one or more of the substantially dispersed particles of the spray is introduced into one or more of the target cells. The spray of substantially dispersed particles may be established by dispensing a spray of microdroplets suspending particles. The electrical charge is concentrated on the suspended particles as the microdroplet evaporates. The suspended particles may include carrier particles with biological material or the suspended particles may be particles of biological material alone. The space charge effect of the concentrated electrical charge on the substantially dispersed particles of the spray enable one or more of the particles to be introduced into one or more of the target cells. An apparatus for introducing biological material into one or more target cells includes a biological material source including at least biological material and a dispensing device operably connected to the biological material source to receive biological material therefrom. The dispensing device provides a spray of substantially dispersed particles of at least the biological material with the spray of substantially dispersed particles having an electrical charge applied thereto.
PURPOSE:To obtain a cosmetic maintaining or restoring skin to a healthy state by promoting water retaining function of skin, providing skin with wetting properties, flexibility, elasticity and gloss, showing excellent skin beautifying effects, by blending a skin cosmetic with a succinate and aloe essence. CONSTITUTION:A skin cosmetic blended with 0.1-5.0wt% succinate and 0.01-1.0wt% aloe essence. An alkali metallic salt, basic amino acid salt (e.g. lysine salt or arginine salt), an alkanolamine salt (e.g. monoethanolamine), etc., may be cited as the succinate and the basic amino acid salt is preferable. Aloe essence extracted from cape aloe, aloe bera, Arborescens Mill. var. natalensis Berg., are suitable as the aloe essence. The skin cosmetic is used in the form of lotion, milky lotion, cream, pack, etc.
Take Typride tablets (Jiangsu Enhua Pharmaceutical Co., Ltd., Guoyao Zhunzi H32025477). Methods: Oral administration half an hour after meals. Dosage: 50mg/time for 4-7 years old, 75mg/time for 7-12 years old, 100mg/time for 10-18 years old, 2 times/d) for 23 cases each, 2 consecutive weeks for 1 course of treatment.
To investigate the value of preoperative ultrasound combined with 99mTc-MIBI imaging for the diagnosis of ectopic intrathyroid parathyroid gland (ETPG) in patients with secondary hyperparathyroidism (SHPT). One hundred and eleven patients with SHPT who underwent total parathyroidectomy plus forearm transplantation from January 2015 to January 2022 in the Third Hospital of Hebei Medical University were selected. All patients underwent routine preoperative ultrasonography and 99mTc-MIBI imaging, and with pathological diagnosis as the gold standard, the clinical data of ETPG patients were selected, including clinical manifestations, laboratory tests, preoperative ultrasonography and 99mTc-MIBI imaging for localization and diagnosis, intraoperative exploration and postoperative pathology, and postoperative follow-up. To analyze the ultrasound manifestations of preoperative parathyroid hyperplasia and the results of 99mTc-MIBI imaging in patients with ETPG. Among 111 patients with SHPT, there were 5 patients with ETPG, 1 male and 4 females with a mean age of (45.00 ± 5.05) years, and 6 ectopic parathyroid glands were located in the thyroid gland. The incidence of ETPG was 4.5% (5/111), 4 were detected by ultrasound, 2 were not detected with a diagnostic accuracy of 66.7% (4/6), 3 were positive for 99mTc-MIBI imaging, 3 were negative with a diagnostic accuracy of 50.0% (3/6). Among them, one was not detected by ultrasound, but was positive for 99mTc-MIBI imaging, 2 with negative 99mTc-MIBI imaging, but all were detected by ultrasound, and one with negative 99mTc-MIBI imaging was detected by ultrasound but misdiagnosed as a thyroid nodule. A total of 5 ETPGs were detected by ultrasound combined with 99mTc-MIBI imaging, with a diagnostic accuracy of 83.3% (5/6). Patients' postoperative serum calcium and serum parathyroid hormone (PTH) levels were normalized or significantly decreased from preoperative levels. Ultrasound combined with 99mTc-MIBI imaging can achieve higher accuracy than either examination alone in the preoperative localization and diagnosis of ETPG in SHPT patients.
<P>PROBLEM TO BE SOLVED: To streamline pharmacy administration by predicting the number of prescriptions variable with a day and time, and managing the stock of drugs and controlling the personnel arrangement of pharmacists accordingly.  <P>SOLUTION: A means for storing an achievement database is provided including numbers of prescriptions and types of prescription drugs handled in the past. The achievement database is tabulated by a day and time to create a prediction database in which the number of prescriptions brought and types of prescription drugs are predicted by a month, day and time. In addition to the achievement database, a medical institution database including service days and times and expertise fields of doctors in a medical institution is stored. From the databases, the number of prescriptions brought is predicted by the month, day and time.  <P>COPYRIGHT: (C)2004,JPO
The utility model relates to a medical item, in which the thin drug containing pad made from paper towels or the gauzes wrapped with a cotton fibre layer is fastened on the central part of a waterproof membrane in which the surroundings are directly coated with adhesive stickers or coated with adhesive stickers after a thin layer is pasted. A protective strip is arranged above the adhesive stickers. According to the use, after the thin drug containing pad is soaked with liquid or discharged with ointments and other drugs, or after the drug is disposed on the affected area, the protective strip on the adhesive sticker of the waterproof membrane surroundings is put off, so that the thin drug containing pad can be clung to the affected area. Thus the adhesive sticker is pasted on the skin around the affected area. The hot towel can be adopted to dispose on the waterproof membrane for foment in order to enhance the efficacy. The utility model has the advantages that not only the use is convenient and the efficacy can be enhanced with the supplementary foment, but also a variety of drugs including liquid can be selected in accordance with the needs of patients. Therefore, the scope of application is extensive.
A peptide of formula R-Ser-Leu-Pro-Ser-Pro-Ser-Arg-Leu- Pro-Gly-Pro-Ser-Asp-Thr-Pro-Ile-Leu- Pro-Gln-OH (I) or its salts are new. In the formula R is H or R1-Ser-Ser-Ser-Ser-Lys- Ala-Pro-Pro-Pro-; R1 is H or R2-3-Asp-Asp-Pro- Arg-Phe-Gln-Asp-; R2 is H or R4-Asp-His-Pro-Leu-Thr-; R3 is Cys or S-acetamidomethl-Cys; R4 is H-R5-Gly-Gly-Pro-Lys-; R5 is Cys or Tyr. HCG is sugar protein and a sexual hormone which plays an important role on support of pregnancy. Determination or detection of HCG is useful for early diagnosis of pregnancy, ectopic pregnancy and choriocarcinoma etc. Antibody obtd. by means of the novel peptide of formula (I) as antigen has immunity cross activity; and so the peptide (I) is useful for prepn. of antibody for HCG determination system and as labelling reagent. End cpd. (I) may be produced by condensing single amino acids or lower peptides in the order shown in formula (I) and eliminating protective gp. for functional gp. of side chain at the final stage of condensn. reaction.
1. Use of an alendronic acid or a pharmaceutically acceptable salt thereof or a mixture thereof in the manufacture of a medicament for inhibiting bone resorption in a mammal wherein said medicament is adapted for oral sequential administration as a unit dosage comprising from about 8.75 to about 140 mg of alendronic acid or a pharmaceutically acceptable salt thereof on an alendronic acid active basis according to a continuous schedule having a periodicity from about once every 3 days to about once every 16 days. 2. Use according to claim 1, wherein said continuous schedule having a dosing interval selected from the group consisting of once-weekly dosing, twice-weekly dosing, bi-weekly dosing, and twice monthly dosing. 3. Use according to claim 1 or 2, wherein said dosing interval is once-weekly. 4. Use according to claim 3, wherein said unit dosage comprises from about 17,5 mg to about 70 mg of alendronic acid or a pharmaceutically acceptable salt thereof on an alendronic acid active basis. 5. Use according to any one of claims 1-4, wherein sodium, potassium, calcium, magnesium or ammonia salts of alendronic acid are used therefor. 6. Use according to any one of claims 1-5, wherein sodium salt of alendronic acid is used therefor. 7. Use according to any one of claims 1-6, wherein monosodium salt of alendronic acid is used therefor. 8. Use according to any one of claims 1-7, wherein alendronic acid or a pharmaceutically acceptable salt thereof is hydrated. 9. Use according to any one of claims 1-8, wherein alendronate monosodium trihydrate is used therefor. 10. Use according to any one of claims 4-8, wherein said unit dosage comprises about 70 mg of alendronic acid or a pharmaceutically acceptable salt thereof on an alendronic acid active basis.